title: Renal function in a rat model of neurogenic bladder, effect of statins and phosphodiesterase-5 inhibitors.
abstract: OBJECTIVE
  Neurogenic bladder is a common complication of several central nervous system injuries. Statins and phosphodiesterase-5 (PDE-5) inhibitors are reportedly beneficial in neural injuries and urinary system dysfunction. The effect of simvastatin, sildenafil and tadalafil on several renal function indices of an animal model of neurogenic bladder was investigated.
  
  
  METHODS
  Forty male rats were assessed in five equal groups. Dura mater and the cord were injured with an aneurysmal clamp at the level of T9-T10 in all rats except in sham group. The sham and control groups (treated by normal saline), simvastatin (4 mg/kg), sildenafil (5 mg/kg), and tadalafil (2 mg/kg) groups received treatment (i.p.) for seven consecutive days following injury. Renal system and motor functions were assessed at day 28 following injury. Data were analyzed by analysis of variance followed by the Student-Newman-Keuls post hoc test.
  
  
  RESULTS
  Simvastatin improved both the renal and the motor function compared with the control group. However, sildenafil and tadalafil could only improve the motor function but could not make any significant differences in renal indices in comparison with the control group.
  
  
  CONCLUSIONS
  Statins can effectively improve the motor and renal functions in a condition of renal dysfunction in a rat model of neurogenic bladder. PDE-5 inhibitors could help to improve motor function, but are not helpful in renal function, at least in short time.
authors.affiliation: Department of Physiology, School of Medicine, Aja University of Medical Sciences, Tehran, Iran, emirzaii@razi.tums.ac.ir.
authors.forename: Iraj
authors.initials: I
authors.lastname: Mirzaii-Dizgah
authors.forename: Bahram
authors.initials: B
authors.lastname: Salmanyan
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D002243:Carbolines / Q000494:pharmacology; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5 / Q000378:metabolism; D004195:Disease Models, Animal; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology; D007668:Kidney / Q000503:physiopathology*; D008297:Male; D009929:Organ Size; D058986:Phosphodiesterase 5 Inhibitors / Q000494:pharmacology*; D010879:Piperazines / Q000494:pharmacology; D011687:Purines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D000068677:Sildenafil Citrate; D019821:Simvastatin / Q000494:pharmacology*; D013450:Sulfones / Q000494:pharmacology; D000068581:Tadalafil; D001743:Urinary Bladder / Q000473:pathology; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy* / Q000503:physiopathology*; D014556:Urine
chemical_list: D002243:Carbolines; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D058986:Phosphodiesterase 5 Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068581:Tadalafil; D019821:Simvastatin; D000068677:Sildenafil Citrate; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5
references.citation: Exp Neurol. 1996 Jun;139(2):244-56
references.pmid: 8654527
references.citation: Yonsei Med J. 1995 Jul;36(3):251-61
references.pmid: 7660676
references.citation: Urol Res. 2005 Nov;33(5):349-57
references.pmid: 16292585
references.citation: Urol Int. 1993;51(2):89-93
references.pmid: 8351761
references.citation: J Inflamm (Lond). 2010 Apr 19;7:17
references.pmid: 20403180
references.citation: J Urol. 2008 Oct;180(4):1228-34
references.pmid: 18722631
references.citation: Exp Neurol. 2008 Dec;214(2):168-80
references.pmid: 18775426
references.citation: J Clin Invest. 1997 Dec 1;100(11):2671-9
references.pmid: 9389730
references.citation: J Clin Neurosci. 2010 Mar;17(3):349-52
references.pmid: 19875292
references.citation: J Urol. 2008 Dec;180(6):2323-9
references.pmid: 18930285
references.citation: Clin Rehabil. 2010 Jul;24(7):579-89
references.pmid: 20584864
references.citation: J Urol. 1997 Jun;157(6):2295-7
references.pmid: 9146656
references.citation: Pediatr Nephrol. 2008 Apr;23(4):541-51
references.pmid: 18270749
references.citation: Am J Physiol Renal Physiol. 2003 Aug;285(2):F303-9
references.pmid: 12697581
references.citation: Br J Pharmacol. 2010 Jul;160(5):1135-43
references.pmid: 20590607
references.citation: Eur Urol. 2010 Oct;58(4):616-25
references.pmid: 20708839
references.citation: Neurourol Urodyn. 2010;29(1):63-76
references.pmid: 20025033
references.citation: Biomed Res. 2007 Oct;28(5):255-9
references.pmid: 18000338
references.citation: Am J Nephrol. 2008;28(2):290-7
references.pmid: 18004065
references.citation: Am J Cardiol. 2006 Mar 1;97(5):748-55
references.pmid: 16490450
references.citation: BJU Int. 2006 Oct;98(4):739-45
references.pmid: 16978269
references.citation: J Urol. 2008 Nov;180(5):2212-7
references.pmid: 18804815